Journal: Clinical Epidemiology
Authors: Rebecca Persson, Katrina Wilcox Hagberg, Catherine Vasilakis-Scaramozza, Eleanor Yelland, Tim Williams, Puja Myles, Susan S Jick
NLM Citation: Persson R, Hagberg KW, Vasilakis-Scaramozza C, Yelland E, Williams T, Myles P, Jick SS. Presence of Codes for Indication for Use in Clinical Practice Research Datalink Aurum: An Assessment of Benign Prostatic Hyperplasia Treatments. Clin Epidemiol. 2022 May 3;14:641-652. doi: 10.2147/CLEP.S360843. PMID: 35535332; PMCID: PMC9078872.
Abstract
Background: Assessments of strengths and limitations of new data sources are critical for making decisions about suitability for specific research questions. For some studies, it is necessary to capture a drug’s indication for use.
Objective: To assess the presence of indications for prescription use in Clinical Practice Research Datalink (CPRD) Aurum (January 1988-June 2021) by describing the proportion of men in CPRD Aurum who had a recorded indication for use of prescriptions for 5-alpha reductase inhibitors (5-ARI), alpha blockers (AB), or tadalafil, which have multiple indications.
Methods: From a random sample of 154 practices of CPRD Aurum data, we selected 85,597 male patients with a prescription for a 5-ARI, an AB, or tadalafil. Among these patients, we described presence of codes indicating whether the patient had benign prostatic hyperplasia, hypertension, erectile dysfunction, or alopecia using three indication definitions: narrow (specific diagnoses recorded within one year before and up to 90 days after the prescription), broad (specific diagnoses or supporting clinical codes in the time period described above), and widest (diagnoses or supporting codes recorded at any time before the prescription and up to 90 days after the prescription).
Results: Using the narrow indication definition limited to diagnoses only, 39,861 (46.6%) patients’ records contained an indication for use. The broad definitions, which additionally included supporting codes, captured indications for 62,912 (73.5%) patients and the widest definition, which additionally included supporting codes and all available data before the first prescription date, captured indications for 71,478 (83.5%) patients. Indications were present more often for prescriptions in 2005 and later (85.9%).
Conclusion: The findings of this assessment suggest that CPRD Aurum can be used for studies that require information on treatment indications for BPH and potentially for treatments of other chronic diseases managed in the primary care setting.
Keywords: CPRD Aurum; Clinical Practice Research Datalink; data element presence; indication for use; pharmacoepidemiology; prostatic hyperplasia.
